Windlas Biotech (WINDLAS) | Financial Analysis & Statements
Windlas Biotech Ltd. Small-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Jun 2025Income Metrics
Revenue
2.1B
Gross Profit
803.6M
38.25%
Operating Income
190.8M
9.08%
Net Income
176.6M
8.41%
EPS (Diluted)
₹8.34
Balance Sheet Metrics
Total Assets
7.6B
Total Liabilities
2.5B
Shareholders Equity
5.1B
Debt to Equity
0.50
Cash Flow Metrics
Revenue & Profitability Trend
Quarter Income Flow
Jun 30, 2025
Annual Income Flow
2025
Windlas Biotech Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 7.6B | 6.3B | 5.1B | 4.6B | 4.3B |
| Cost of Goods Sold | 4.7B | 4.0B | 3.3B | 3.0B | 2.7B |
| Gross Profit | 2.8B | 2.3B | 1.9B | 1.6B | 1.5B |
| Gross Margin % | 37.5% | 37.0% | 36.3% | 34.6% | 35.7% |
| Operating Expenses | |||||
| Research & Development | 62.5M | 78.8M | 89.5M | 65.1M | 36.1M |
| Selling, General & Administrative | 245.1M | 258.4M | 186.1M | 154.5M | 119.4M |
| Other Operating Expenses | 387.1M | 348.5M | 289.1M | 243.7M | 219.4M |
| Total Operating Expenses | 694.8M | 685.7M | 564.7M | 463.3M | 374.9M |
| Operating Income | 666.1M | 647.3M | 479.2M | 405.9M | 443.3M |
| Operating Margin % | 8.8% | 10.3% | 9.4% | 8.8% | 10.4% |
| Non-Operating Items | |||||
| Interest Income | 15.4M | 19.7M | 34.9M | 42.8M | 19.2M |
| Interest Expense | 43.8M | 11.0M | 7.9M | 14.2M | 12.9M |
| Other Non-Operating Income | - | - | - | - | - |
| Pre-tax Income | 797.6M | 770.9M | 570.4M | 455.6M | 217.4M |
| Income Tax | 187.6M | 189.0M | 144.1M | 74.8M | 61.7M |
| Effective Tax Rate % | 23.5% | 24.5% | 25.3% | 16.4% | 28.4% |
| Net Income | 609.9M | 581.9M | 426.3M | 380.9M | 155.7M |
| Net Margin % | 8.1% | 9.3% | 8.3% | 8.2% | 3.6% |
| Key Metrics | |||||
| EBITDA | 971.5M | 808.1M | 646.0M | 575.8M | 320.8M |
| EPS (Basic) | ₹29.19 | ₹27.97 | ₹19.70 | ₹18.58 | ₹8.69 |
| EPS (Diluted) | ₹28.87 | ₹27.88 | ₹19.70 | ₹18.58 | ₹4.86 |
| Basic Shares Outstanding | 20895025 | 20806285 | 21635920 | 20497174 | 18220708 |
| Diluted Shares Outstanding | 20895025 | 20806285 | 21635920 | 20497174 | 18220708 |
Income Statement Trend
Join Our India Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Windlas Biotech Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 4.2M | 52.9M | 36.9M | 5.7M | 159.3M |
| Short-term Investments | 2.4B | 2.0B | 1.3B | 1.8B | 383.2M |
| Accounts Receivable | 1.7B | 1.4B | 1.2B | 1.1B | 794.1M |
| Inventory | 813.8M | 621.9M | 747.4M | 587.1M | 414.6M |
| Other Current Assets | 333.1M | 262.2M | 285.0M | -10.0K | 12.7M |
| Total Current Assets | 5.3B | 4.3B | 3.5B | 3.8B | 1.9B |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 65.8M | 58.5M | 37.4M | 36.4M | 34.8M |
| Goodwill | 67.8M | 44.7M | 14.8M | 8.8M | 4.8M |
| Intangible Assets | 67.8M | 44.7M | 14.8M | 8.8M | 4.8M |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 500.0K | -10.0K | 415.9M | 20.0K | - |
| Total Non-Current Assets | 2.4B | 1.9B | 1.8B | 1.1B | 1.0B |
| Total Assets | 7.6B | 6.3B | 5.3B | 4.9B | 3.0B |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 1.7B | 1.3B | 877.4M | 632.3M | 399.3M |
| Short-term Debt | 303.5M | 16.2M | 18.7M | 61.9M | 310.0M |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | 127.7M | 46.7M | 41.5M | 15.0M | - |
| Total Current Liabilities | 2.5B | 1.7B | 1.2B | 939.9M | 934.2M |
| Non-Current Liabilities | |||||
| Long-term Debt | 22.5M | 20.2M | 31.3M | 4.4M | 13.5M |
| Deferred Tax Liabilities | - | - | - | 0 | 6.8M |
| Other Non-Current Liabilities | - | - | - | 40.0K | - |
| Total Non-Current Liabilities | 52.4M | 45.2M | 54.6M | 22.5M | 35.8M |
| Total Liabilities | 2.5B | 1.8B | 1.3B | 962.3M | 970.0M |
| Equity | |||||
| Common Stock | 104.8M | 104.0M | 104.6M | 109.0M | 64.1M |
| Retained Earnings | 2.7B | 2.3B | 1.8B | 1.4B | 1.0B |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 5.1B | 4.5B | 4.0B | 3.9B | 2.0B |
| Key Metrics | |||||
| Total Debt | 326.0M | 36.4M | 49.9M | 66.4M | 323.5M |
| Working Capital | 2.8B | 2.6B | 2.3B | 2.9B | 1.0B |
Balance Sheet Composition
Windlas Biotech Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | 797.6M | 770.9M | 570.4M | 455.6M | 217.4M |
| Depreciation & Amortization | - | - | - | - | - |
| Stock-Based Compensation | 24.6M | 20.7M | 10.1M | 18.1M | 0 |
| Working Capital Changes | -454.9M | -3.1M | -187.6M | -611.1M | 64.6M |
| Operating Cash Flow | 396.8M | 779.8M | 366.4M | -162.9M | 278.6M |
| Investing Activities | |||||
| Capital Expenditures | -520.0M | -376.4M | -699.8M | -146.9M | -58.3M |
| Acquisitions | - | - | - | 0 | -1.0B |
| Investment Purchases | - | - | - | - | -147.4M |
| Investment Sales | - | - | - | - | 1.0B |
| Investing Cash Flow | -520.0M | -376.4M | -699.8M | -146.9M | -218.6M |
| Financing Activities | |||||
| Share Repurchases | 0 | -40.2M | -271.9M | 0 | - |
| Dividends Paid | -115.0M | -83.0M | -76.3M | - | - |
| Debt Issuance | - | - | - | - | - |
| Debt Repayment | 0 | -1.1M | -3.4M | -3.9M | -45.8M |
| Financing Cash Flow | 199.4M | -126.6M | -405.0M | 1.4B | 38.8M |
| Free Cash Flow | 159.9M | 712.8M | -99.2M | -56.7M | 56.1M |
| Net Change in Cash | 76.3M | 276.8M | -738.4M | 1.1B | 98.8M |
Cash Flow Trend
Windlas Biotech Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
27.93
Price to Book
3.45
Price to Sales
2.14
PEG Ratio
-6.31
Profitability Ratios
Profit Margin
7.69%
Operating Margin
7.16%
Return on Equity
12.06%
Return on Assets
8.02%
Financial Health
Current Ratio
2.06
Debt to Equity
5.84
Beta
0.22
Per Share Data
EPS (TTM)
₹31.45
Book Value per Share
₹254.44
Revenue per Share
₹413.54
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| WINDLAS | 18.2B | 27.93 | 3.45 | 12.06% | 7.69% | 5.84 |
| Sun Pharmaceutical | 3.9T | 36.73 | 5.15 | 15.08% | 19.21% | 6.68 |
| Divi's Laboratories | 1.7T | 67.11 | 10.82 | 14.64% | 24.04% | 0.58 |
| Sun Pharma Advanced | 46.7B | -13.65 | -13.55 | 157.88% | -53.22% | -1.21 |
| Innova Captab | 41.4B | 31.20 | 4.05 | 13.37% | 8.85% | 32.95 |
| Gujarat Themis | 35.4B | 73.73 | 13.36 | 19.64% | 29.99% | 27.04 |
Financial data is updated regularly. All figures are in the company's reporting currency.





